Former VP, Head of Portfolio Strategy and Management, AstraZeneca/MedImmune
Kristi is an accomplished business leader with a strong track record in establishing strategic vision and building strong teams and partnerships that deliver results. She has demonstrated the ability to apply scientific, development and business acumen for successful commercialization, value creation and revenue growth across multiple therapeutic areas and organizations. She is a Board and Executive Committee advisor and consultant to multiple start-up companies focusing on strategy, risk, value creation, communication and business development.
At Astra Zeneca, Kristi’s responsibilities included partnering with Executive committee and Board members, leading portfolio planning and decision making, driving prioritization and shaping portfolio and product strategies and plans. Kristi’s efforts were instrumental in driving a refined enterprise vision and increasing the value of the portfolio by $12B. Additional responsibilities included integrating the portfolio with the business plan, establishing corporate goals, milestones and performance tracking, and streamlining organizational processes to increase speed, quality and transparency of key decisions.
Kristi joined Astra Zeneca in 2013 from MedImmune where she held the Vice President, Global Strategic Marketing and Payor Strategy role (2011-2013). As a global leader, she was responsible for all commercialization efforts, recommendations and shaping the business for ~30 biologic molecules from pre-clinical to Phase 3. She providing strategic guidance on opportunities, investment decisions, business development and establishing enterprise launch readiness plans.
Prior to MedImmune, Kristi spent 16 years at Genentech in multiple global and US commercial leadership roles spanning strategy and operations. She has consistently demonstrated the ability to drive revenue growth through strong collaboration, innovative strategies and excellence in execution across multiple products and TA’s.
She holds a Bachelor of Science degree from Texas Tech, and Pharmacy degree from the University of Texas and has been involved in multiple programs at Berkeley, Stanford and Harvard focused on strategy, biotechnology, and leadership.